Skip to main content
OpenTrials
Completed

NCT Number: NCT00279578

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

In the present study we are examining the clot formation and clot stability in patients with severe haemophilia A after they receive recombinat factor VIII and after addition of tranexamic acid. Our hypothesis is that addition of tranexamic increases the clot stability. The perpective of the study is to document whether it is relevant to use traneksamic acid in surgery in patients with severe haemophilia A.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemophilia A Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Department of Clinical Biochemistry, Center for Haemophilia and Thrombosis

Aarhus, 8200, Denmark

About this study

In the present study we are examining the clot formation and clot stability in patients with severe haemophilia A after they receive recombinat factor VIII and after addition of tranexamic acid. Our hypothesis is that addition of tranexamic increases the clot stability. The perpective of the study is to document whether it is relevant to use traneksamic acid in surgery in patients with severe haemophilia A.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Severe haemophilia A
  • Above 17 years old
  • Thrombocyt count above 100 x 109/l within the past two years

Exclusion criteria

  • Received recombinant factor VIII with in the past 3 days
  • Inhibitor against recombinant factor VIII
  • HIV-positive
  • Ongoing treatment for hepatitis C
  • Known kidney disease
  • Allergy against Tranexamic acid
  • Not able to give informed consent

Treatment and study plan

ReFacto (Recombinant factor VIII) and Tranexamic acid

Drug

Primary outcomes

  1. Clot stability

Secondary outcomes

  1. clot formation,thrombine generation

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Official study title

Clot Formation and Clot Stability in Patients With Severe Haemophilia A - Effect of Recombinant Factor VIII and Tranexamic Acid

Important dates

Study start
2006
Study completion
2006
First posted
Jan 19, 2006
Registry last updated
Nov 16, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.